NO953270L - Fibrinogenreceptorantagonister - Google Patents

Fibrinogenreceptorantagonister

Info

Publication number
NO953270L
NO953270L NO953270A NO953270A NO953270L NO 953270 L NO953270 L NO 953270L NO 953270 A NO953270 A NO 953270A NO 953270 A NO953270 A NO 953270A NO 953270 L NO953270 L NO 953270L
Authority
NO
Norway
Prior art keywords
fibrinogenreceptorantagonister
compounds
abncn
formula
receptor antagonist
Prior art date
Application number
NO953270A
Other languages
English (en)
Other versions
NO953270D0 (no
Inventor
David Alan Claremon
John J Baldwin
Nigel Liverton
Ben Askew
Original Assignee
Merck & Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck & Co Inc filed Critical Merck & Co Inc
Publication of NO953270D0 publication Critical patent/NO953270D0/no
Publication of NO953270L publication Critical patent/NO953270L/no

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/164Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A61K38/166Streptokinase
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46Hydrolases (3)
    • A61K38/48Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/49Urokinase; Tissue plasminogen activator
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Forbindelser ifølge oppfin- nelsen har formel (l) eller (2) O R2 R6 Q-(CH2)n-a-AB¿C-N-RS-C-R" m i- !,- O R2 R6 II l l Q-(CH2)n-a-AB¿C-Rs-c-R8 (2) R1 for eksempel (3). <w> (3) Forbindelsene har fibrinogenreseptor- antagonistaktivitet.
NO953270A 1993-02-22 1995-08-21 Fibrinogenreceptorantagonister NO953270L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US2051793A 1993-02-22 1993-02-22
PCT/US1994/001881 WO1994018981A1 (en) 1993-02-22 1994-02-22 Fibrinogen receptor antagonists

Publications (2)

Publication Number Publication Date
NO953270D0 NO953270D0 (no) 1995-08-21
NO953270L true NO953270L (no) 1995-10-19

Family

ID=21799049

Family Applications (1)

Application Number Title Priority Date Filing Date
NO953270A NO953270L (no) 1993-02-22 1995-08-21 Fibrinogenreceptorantagonister

Country Status (15)

Country Link
EP (1) EP0684823A4 (no)
JP (1) JP3173792B2 (no)
KR (1) KR960700722A (no)
CN (1) CN1118139A (no)
AU (1) AU680240B2 (no)
BG (1) BG99863A (no)
CA (1) CA2155123A1 (no)
CZ (1) CZ210895A3 (no)
FI (1) FI953916A7 (no)
HU (1) HUT71796A (no)
NO (1) NO953270L (no)
NZ (1) NZ262664A (no)
PL (1) PL310386A1 (no)
SK (1) SK102495A3 (no)
WO (1) WO1994018981A1 (no)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5849736A (en) * 1993-11-24 1998-12-15 The Dupont Merck Pharmaceutical Company Isoxazoline and isoxazole fibrinogen receptor antagonists
US5494921A (en) * 1994-09-16 1996-02-27 Merck & Co., Inc. Fibrinogen receptor antagonists
ZA963391B (en) * 1995-05-24 1997-10-29 Du Pont Merck Pharma Isoxazoline fibrinogen receptor antagonists.
BR9610422A (pt) * 1995-08-30 1999-07-13 Searle & Co Derivados de meta-guanidina uréia tiouréia ou ácido aminobenzóico azacíclico como antagonistas de integrina
US6100423A (en) * 1995-08-30 2000-08-08 G. D. Searle & Co. Amino benzenepropanoic acid compounds and derivatives thereof
DE69633245T2 (de) 1995-09-29 2005-09-08 Eli Lilly And Co., Indianapolis Spiroverbindungen als Inhibitoren der Fibrinogen-abhängigen Blutplättchenaggregation
EP0939757A1 (en) * 1995-12-22 1999-09-08 Dupont Pharmaceuticals Company Novel integrin receptor antagonists
AU2340997A (en) * 1996-03-27 1997-10-17 Merck & Co., Inc. A method for inhibiting clot formation
SG124234A1 (en) * 1996-07-25 2006-08-30 Biogen Idec Inc Cell adhesion inhibitors
US5900414A (en) * 1996-08-29 1999-05-04 Merck & Co., Inc. Methods for administering integrin receptor antagonists
DE19653647A1 (de) * 1996-12-20 1998-06-25 Hoechst Ag Vitronectin - Rezeptorantagonisten, deren Herstellung sowie deren Verwendung
JP2001512439A (ja) * 1997-02-06 2001-08-21 メルク エンド カンパニー インコーポレーテッド 線維素原受容体拮抗薬プロドラッグ
WO1998043962A1 (en) * 1997-03-28 1998-10-08 Du Pont Pharmaceuticals Company Heterocyclic integrin inhibitor prodrugs
US6303625B1 (en) 1998-07-27 2001-10-16 Ortho-Mcneil Pharmaceutical, Inc. Triazolopyridines for the treatment of thrombosis disorders
SK1182002A3 (en) * 1999-07-28 2002-11-06 Aventis Pharm Prod Inc Substituted oxoazaheterocyclyl compounds
CN1747949A (zh) * 2002-12-20 2006-03-15 法马西亚公司 无环吡唑化合物
US20100035756A1 (en) * 2006-07-12 2010-02-11 Syngenta Limited Triazolophyridine derivatives as herbicides
US8088792B2 (en) 2008-04-04 2012-01-03 Gilead Sciences, Inc. Triazolopyridinone derivatives for use as stearoyl CoA desaturase inhibitors
WO2010096722A1 (en) * 2009-02-20 2010-08-26 Takeda Pharmaceutical Company Limited 3-oxo-2, 3-dihydro- [1,2, 4] triazolo [4, 3-a]pyridines as soluble epoxide hydrolase (seh) inhibitors

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5084466A (en) * 1989-01-31 1992-01-28 Hoffmann-La Roche Inc. Novel carboxamide pyridine compounds which have useful pharmaceutical utility
GB8913011D0 (en) * 1989-06-06 1989-07-26 Wellcome Found Anticonvulsant pyrazines
US5166154A (en) * 1989-10-17 1992-11-24 Boehringer Ingelheim Pharmaceuticals, Inc. Imidazo[1,2-a]piperazines
US5278161A (en) * 1990-06-28 1994-01-11 Hoffmann-La Roche Inc. Amino acid derivatives useful as renin inhibitors

Also Published As

Publication number Publication date
JP3173792B2 (ja) 2001-06-04
FI953916A0 (fi) 1995-08-21
CA2155123A1 (en) 1994-09-01
BG99863A (bg) 1996-02-29
FI953916L (fi) 1995-08-21
PL310386A1 (en) 1995-12-11
WO1994018981A1 (en) 1994-09-01
AU6246594A (en) 1994-09-14
CZ210895A3 (en) 1996-02-14
FI953916A7 (fi) 1995-08-21
HUT71796A (en) 1996-02-28
JPH08507072A (ja) 1996-07-30
EP0684823A1 (en) 1995-12-06
HU9502028D0 (en) 1995-09-28
CN1118139A (zh) 1996-03-06
KR960700722A (ko) 1996-02-24
EP0684823A4 (en) 1997-07-09
NZ262664A (en) 1997-04-24
NO953270D0 (no) 1995-08-21
AU680240B2 (en) 1997-07-24
SK102495A3 (en) 1997-01-08

Similar Documents

Publication Publication Date Title
NO953270L (no) Fibrinogenreceptorantagonister
DE69006131D1 (de) Substituierte Chinazolinone als Angiotensin II-Antagonisten.
YU157191A (sh) Antagonisti receptora fibrinogena
MX9102407A (es) 4 arilpiperazinas y 4-arilpiperidinas novedosas.
TR200101155T2 (tr) 4-Aroil Piperidin CCR-3 Reseptör Antagonistleri III
TR200101961T2 (tr) 1,2-halkalı kinolin türevleri
EA200000098A1 (ru) 4-АМИНОПИРРОЛ(3,2-d)ПИРИМИДИНЫ В КАЧЕСТВЕ АНТАГОНИСТОВ РЕЦЕПТОРА НЕЙРОПЕПТИДА Y
ATE37375T1 (de) Phosphonyl-hydroxyacyl-aminosaeure-derivate und ihre verwendung als antihypertensiva.
ATE203670T1 (de) Verwendung von östrogenantagonisten und - agonisten zur hemmung pathologischer zustände
NO971538L (no) Purin- og guaninforbindelser som inhibitorer for PNP
ATE206409T1 (de) N-(1-alkyl-5-phenyl-2,3,4,5-tetrahydro-1-h- benzo(b)(1,5)-diazepin-3-yl)-acetamide
FR2399430A1 (fr) Chlorhydrate dihydrate de 1-(4-amino-6, 7-dimethoxy-2-quinazolinyl)-4- (2-tetrahydrofuroyl)piperazine, et son utilisation comme agents antihypertensif
EP0698023A4 (en) FIBRINOGEN RECEPTOR ANTAGONISTS
NO943100L (no) Forbindelser for anvendelse i kontrastmidler for radiografi
ATE198202T1 (de) Fibrinogen receptor antagonisten
DK0696278T3 (da) Herbicidtvirkende substituerede 1-phenyl- eller 1-pyridinylbenzotriazoler
NO972887L (no) Piperidineddiksyrederivater anvendelige som fibrinogen-antagonistmiddel
TR200101979T2 (tr) Antidepresyon tedavisi için 5HT1 antagonistleri.
SE8500107L (sv) Nya 8-alfa-acylaminoergoline
TR200001222T2 (tr) Yeni tetrasiklikler, bunların üretimi için işlem ve bu birleşikleri içeren farmasötik preparasyonlar.
ES8701159A1 (es) Procedimiento para la obtencion de derivados de piperidina con actividad cardiovascular.
NO20002408D0 (no) 5-HT1F antagonister
ES2062389T3 (es) Acidos glutaramicos sustituidos y sus derivados.
DK365284A (da) 5-substituerede (1,2,4)triazolo(1,5-c)pyrimidin-2-aminer
DE69017627D1 (de) Isochinolinderivate und ihre Salze als Proteasehemmer.